• April 7 - 11, San Francisco

    2014 Joint Summits on Translational Science

2014 Joint Summits Lunch and Learn

Lunch and Learns are included in the cost of registration. Please indicate which Lunch and Learn you plan to attend in the Tracks/Sessions section of your event registration.

Tuesday, April 8 12:15 p.m. – 1:15 p.m.

Precision Medicine Ascendant: Supporting the Clinical Use of Omics Data

Frederick Lee, MD, MPH, Director, Clinical & Translational Informatics, Oracle Health Sciences; Andrew Boudreau, Product Strategist, Precision Medicine, Oracle Health Sciences

We have witnessed a sea change in industry attitude towards clinical use of omics data over the last two years, with several pioneers investing significantly in clinical omics strategies focused at the point of care. In this session, the audience will learn:

  • How the first adopter cohort has leveraged enterprise foundational efforts in translational research towards powering strategies in clinical genomics & precision medicine.
  • How a second wave of adopters have mobilized in launching their clinical omics strategies.
  • How the ‘playbooks’ being established by these early adopters can be leveraged by organizations seeking to launch their own clinical omics efforts.
  • How the informatics solutions vendors such as Oracle have responded to this emerging demand around clinical omics.

Wednesday, April 9 12:15 p.m. – 1:15 p.m.

ICD10 and Meaningful Use - Opportunity for Innovation

Regis Charlot, MS, President and Chief Technology Officer, Intelligent Medial Objects, Inc.

Interface terminology modeling has been positive force in supporting our healthcare transformations and regulatory compliance for ICD10 and Meaningful use.  Use of natural language processing and preforming retrospective patient-centric discovery through sophisticated concept tagging is now possible.  Connecting our user community to a semantic highway constructed on comprehensive, clinical concept-based interface terminology will be critical for the future of all healthcare organizations and the distribution of HIT innovations.  In this presentation, Mr. Charlot will discuss “The Semantic Highway” and outline a new way for healthcare providers currently using IMO as their terminology foundation to create a launching point for innovations that will allow them to thrive in the new healthcare reimbursement environment.   Topics include:

  • What is the Semantic Highway?
  • Describing a real time messaging pathway based on medical concepts
  • Having a concept-based semantic highway as a necessary first step to connecting point of care and research centers
  • Exploring the necessary roles of the Semantic highway for semantically-based commerce
  • Empowering clinicians and researchers to connect in real time via interface terminology
  • Intersecting Academic and Corporate worlds: Exploring academic and corporate symbiotic relationships
  • Providing for the accelerated expansion of IMO terminology solutions for IMO’s clinician users and vendor-partners

Thursday, April 10 12:15 p.m. – 1:15 p.m.

UC-ReX, Two Years In – Lessons Learned, Future Plans

Lisa Dahm, PhD, Director of Clinical Informatics for UC-ReX, Director Center for Biomedical Informatics, UC Irvine

The UC-ReX network provides federated access to 12.5 million de-identified patient records across the University of California’s five health sciences campuses. What has been learned in building this network, and what are the future plans for enhancing its utility to the clinical research community?

Precision Medicine, Precision Miner – A Discovery Workbench

Michael Kamerick, Specialist Leader, Informatics, ConvergeHEALTH; Matvey Palchuk, CMIO, ConvergeHEALTH

The goal of precision medicine requires us to develop algorithms that accurately align a patient’s clinical phenotype with their molecular profile in order to arrive at highly specific treatment decisions. How do we develop such algorithms for use in clinical decision support systems? We discuss the Precision Miner tool suite from ConvergeHEALTH by Deloitte and its role as a development environment for the creation of the essential models for personalized, precision medicine.